20/20 BIOLABS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
20/20 BIOLABS, INC. (AIDX) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $3.39 per share as of 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2026-05-20
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $3.39.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $2.55.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price |
|---|---|
| 2026-03-31 | $3.39 10-Q · filed 2026-05-20 |
| 2025-12-31 | $2.55 POS AM · filed 2026-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGENOMICS INC (NEO) | United States | $2.514B | -35.96 |